Clinical Studies Applying Physical Plasma in Head and Neck Cancer - Key Points and Study Design

doi:10.15344/2456-8007/2016/103

Graphy

Profile

New User

New to Graphy Publications? Create an account to get started today.

Create Account For:

Registered Users

Have an account? Sign in now.

Article Menu

Journal Menu

How to Cite | Author Information | Publication History

International Journal of Clinical Research & Trials Volume 1 (2016), Article ID 1:IJCRT-103, 2 pages
https://doi.org/10.15344/2456-8007/2016/103

Commentary

Clinical Studies Applying Physical Plasma in Head and Neck Cancer - Key Points and Study Design

Philine H. Metelmann^1*, David S. Nedrelow², Matthias Schuster³, Rico Rutkowski³, Christian Seebauer³

¹Greifswald University Dental School, Department of Orthodontics, Walter-Rathenau-Str. 42, 17475 Greifswald, Germany
²University of Minnesota, Department of Biomedical Engineering, Minneapolis, MN, USA
³Greifswald University Medicine, Department of Oral and Maxillofacial Surgery/Plastic Surgery, Ferdinand-Sauerbruch-Str. DZ 7, 17475 Greifswald, Germany

Corresponding Author Details: Dr. Philine H. Metelmann, Greifswald University Dental School, Department of Orthodontics, Walter-Rathenau-Str. 42, 17475 Greifswald, Germany; E-mail: metelmannp@uni-greifswald.de

Received: 25 January 2016; Accepted: 18 April 2016; Published: 20 April 2016

Citation: Metelmann PH, Nedrelow DS, Schuster M, Rutkowski R, Seebauer C (2016) Clinical Studies Applying Physical Plasma in Head and Neck Cancer- Key Points and Study Design. Int J Clin Res Trials 1: 103. doi: https://doi.org/10.15344/2456-8007/2016/103

Copyright: © 2016 Metelmann et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Cold atmospheric pressure plasma (CAP) is known to very effectively inactivate multi-resistant strains of microorganisms. Whether or not application of CAP also inactivates cancer cells is a matter of intense clinical interest. There is a need for prospective, randomized, blindly evaluated clinical trials. This paper outlines the key points of such a study program.

Best viewed in Mozilla Firefox, Google Chrome, Safari, Above IE 9.0 version